Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia (Alpha1-Proteinase Inhibitor -Human); this ...
Glassia bottle Shire and Kamada announced that the Food and Drug Administration (FDA) has approved Glassia (alpha-1 proteinase inhibitor [human]) as the first treatment for adults with emphysema due ...
Kamada Ltd. (NASDAQ:KMDA) and U.S. distributor Shire plc (SHPG) announce that the FDA has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] allowing for self-infusion at ...
Shire’s emphysema therapy Glassia has received FDA approval for an expanded label, marking the first time that patients can self-infuse at home. Glassia, an alpha-1 proteinase inhibitor, is licensed ...
Kamada Ltd. KMDA announced that it has extended the strategic partnership with Shire plc SHPG for Glassia for the fourth time since 2010. Glassia, a ready-to-infuse liquid alpha1-proteinase inhibitor, ...
REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced an amendment to the GLASSIA® [Alpha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results